Age: 60.0
Sex: F
Vaccine: COVID19
Symptoms: Vital signs measurement, White blood cell count
Clinical narrative: Diagnosis of Angioimmunoblastic T Cell Lymphoma After Receiving First Dose of Pfizer/BioNTech (BNT162b2) Vaccine; This is a literature report for the following literature source(s).  A 60-year-old female patient with a medical history of distant, resected melanoma in situ received her first dose of Pfizer/BioNTech (BNT162b2) mRNA vaccine in Aug2021. On the same day, she noticed palpable right axillary lymph node (LN) enlargement. She received the second dose of the same vaccine as per the vaccine schedule 4 weeks later. Thereafter, she noticed multiple other LN enlargements in her neck and groin area as well. She visited her primarycare physician for an annual visit around 6 months from her first vaccine dose. Because of persistent LN enlargement and nonspecific B symptoms, the physician recommended an excisional biopsy of the enlarged posterior cervical and left inguinal LNs. The LN pathology revealed benign follicular hyperplasia with positive cells for Epstein-Barr virus (EBV), with no evidence of malignancy. However, due to persistent LN enlargement and B-symptoms, an oncology referral was sent. Oncology evaluation and workup revealed diffuse lymphadenopathy noted on contrast-enhanced computed tomography (CT) chest, abdomen, and pelvis. Her initial laboratory work-up was normal including hemoglobin, white blood cell count, and platelet counts, except LDH 525 U/L. Around 2 weeks later from her oncology appointment, she presented to the emergency department (ED) with acute onset intractable nausea and vomiting associated with generalized weakness and fatigue. In the ED, vitals were stable, but lab work-up revealed her hemoglobin 6.1 g/dL, hematocrit 13%, platelet count 356,000/ uL, LDH 737 U/L, total bilirubin 6.0 mg/dL, indirect bilirubin 5.3 mg/dL, and undetectable haptoglobin. The initial peripheral smear showed significant agglutination rendering nonanalysis of reticulocyte count and direct Coombs testing. The patient was accordingly diagnosed with acute hemolytic anemia (AIHA) and admitted for prednisone 80 mg per day, rituximab, and blood transfusion as needed. After discussion with inpatient oncology services, she underwent an excisional biopsy of the right axillary LN, which was her primary LN which had enlarged following the initial vaccination. Pathology showed effaced nodal architecture by atypical lymphoid infiltration composed of a mixture of small lymphocytes with nuclei that showed condensed chromatin and medium-sized cells with round to irregular nuclei and clear cytoplasm. In the background, there was prominent vascular proliferation and numerous inflammatory cells. Immunohistochemistry on the right axillary LN specimen showed infiltrates that marked as a neoplastic population with CD3 (dim)-positive T cells that co-expressed CD4, CD2, CD5, TCR beta F1, dim to diminished expression of CD7, and high Ki-67 proliferation index. They also expressed the TFH cell marker CD10, some of which associated with focally expanded CD21-positive follicular dendritic cell meshwork. Fluorescence in situ hybridization (FISH) was positive for Epstein-Barr virus-encoded RNA (EBER). The above description was consistent with the diagnosis of angioimmunoblastic T-cell lymphoma as shown in Image: A: low power microscopic image showing effaced lymph node architecture  with prominent blood vessels and atypical medium sized cells with clear cytoplasm. A polymorphous infiltrate including small lymphocytes, plasma cells and numerous eosinophils is present. (H&E 200X original magnification). B: larger atypical lymphocytes with pale cytoplasm, vesicular chromatin and nucleoli are present. The cell indicated by the arrow has a characteristic immunoblastic appearance. Eosinophilic infiltration is prominent. (H&E 1000X original  magnification). C: strong expression or programmed cell death-1 (PD-1/CD279 on immunostained sections highlighting then umerous PD1 positive neoplastic cells present (IHC/immunopemxidase method 1000X original magnification). D: ICOS/CD278 immunostain result is positive in the malignant cells, supporting t-follicular helper origin of the neoplastic cells. (Immunostain immunoperoxidase method 1000x original magnification). E: CXCL13 Immunostain is positive in the atypical lymphoid cells and also supports a T-follicular helper cell phenotype. (Immunostain/immunoperoxidase method 1000x original magnification). Following the diagnosis of angioimmunoblastic T-cell lymphoma, a positron emission tomography/computed tomography (PET/CT) scan was performed and showed hypermetabolic lymphadenopathy in the involved LNs. There was no evidence of disease in the bone marrow. Following stabilization of her AIHA with steroids and rituximab, the patient was discharged from the hospital. After shared decision-making, she received 6 cycles of CHOEP regiment with cyclophosphamide 750 mg/m2, doxorubicin 50 mg/m2, vincristine 1.4 mg/m2 on day 1, etoposide 100 mg/m2 iv over 60 minutes daily on days 1 to 3 and prednisone at 100 mg daily PO days 1 to 5 total (CHOEP) as per the guidelines. Repeat interim PET/CT following cycle 3 showed excellent response with no hypermetabolic lymphadenopathy. She eventually underwent autologous stem cell transplant and has been in complete remission since then. The case showed the expected course of lymphadenopathy as described above. Unfortunately, those hypermetabolic responses were not only reactive changes but were associated with the development of AITL. Although the initial biopsy showed benign follicular hyperplasia, but the persistent lymphadenopathy, presence of B symptoms, detection of EBV, and development of AIHA suggested underlying hematological malignancy and prompted to proceed with another excisional biopsy of the right axilla. It is unclear, however, whether AITL appeared de novo or was simply unmasked after vaccination with underlying mutations TET-2, IDH, RHOA G17V.; Sender's Comments: The event angioimmunoblastic T-cell lymphoma is conservatively assessed as related to the suspect drug BNT162B2 based on close temporal association but consider also possible contributory effects from medical history of the patient and/or concomitant medications. The impact of this report on the benefit/risk profile of the Pfizer product is evaluated as part of Pfizer procedures for safety evaluation, including the review and analysis of aggregate data for adverse events. Any safety concern identified as part of this review, as well as any appropriate action in response, will be promptly notified to Regulatory Authorities, Ethics Committees, and Investigators, as appropriate.,Linked Report(s) : US-PFIZER INC-PV202400066486 Same article/drug/event/patient and different dose;